Episode19_620x292

Episode 19 | Season 1

Transforming Psoriasis Outcomes for Patients, with special guest Leah Howard of the National Psoriasis Foundation

More than 8 million people in the U.S. live with psoriatic disease. Psoriasis and psoriatic arthritis (PsA) can develop at any age and they both have physical, mental, financial and emotional impacts.

Psoriatic disease is chronic and impacts the entire body – from lesions on the skin to permanent joint damage. Psoriatic disease diagnosis, treatment, and management is uniquely challenging, and unfortunately, far too many people are not receiving the treatment they need, or are undertreating.

In today’s episode, Murray discusses the partnership between the National Psoriasis Foundation (NPF) and Happify Health with Leah Howard, interim president and CEO of NPF, and Theo Ahadome, an SVP at Happify Health. The goal of the partnership is to unleash the tools and resources needed—including digital therapeutics— to help those affected manage – and even thrive with – the disease. Tune in for a lively and informative discussion.

 

 

 

Listen to Charting a New Course

 

Featured Guest

1639658308099

Leah Howard

CEO, National Psoriasis Foundation

Leah Howard, J.D., is the President & CEO of the National Psoriasis Foundation. She is a non-profit executive with a demonstrated history of success in developing and advancing the priorities of health care organizations. Howard joined the National Psoriasis Foundation in 2012 and was appointed to the role of Interim President and CEO, effective January 1, 2022. She previously served as NPF Chief Operating Officer (2017 – 2021) providing the strategic direction, vision and leadership to Foundation mission-related functions of government relations and advocacy, marketing and communications, and patient services (education, volunteer outreach and the NPF Patient Navigation Center). Prior to this role, Howard directed the Advocacy and Government Relations department (2012 – 2017). Howard has led a number of major initiatives for the NPF including development of the current (FY2020-2024) Strategic Plan, leading the planning for the 2016 FDA Patient Focused Drug Development (PFDD) meeting, engagement with value assessors, and the NPF annual payer roundtable series. She brings to her role more than 20 years of experience working with national health and disability organizations, local governments, and leading health care and research institutions. Howard has a bachelor of arts degree in government and international relations from the University of Notre Dame and a law degree from George Mason University School of Law. She is based out of the NPF office in Alexandria, VA. 

Hosted By

murray_sq

Murray Zucker, MD

CMO, Happify Health

Murray Zucker, MD, is the chief medical officer at Happify Health. Dr. Zucker has worked as a healthcare consultant and psychiatrist for more than 20 years. He's had senior leadership roles as a medical executive in the health insurance and managed care industries. He has consulted for large hospital systems and Fortune 500 companies, as well as for large provider groups. As a healthcare expert, Dr. Zucker has appeared on the “Today” show, “Good Morning America”, “20/20”, CNN, and the LA evening news. He has also been a featured guest host on radio programs and a quoted expert in prominent media outlets such as The Wall Street Journal, the Los Angeles Times, and People magazine.

theo ahadome

Theo Ahadome

Senior Vice President of Commercialization, Pharma Specialty Solutions

Theo is responsible for establishing and expanding Happify's relationship with pharmaceutical and medical device companies to deliver evidence-based digital therapies for patients. Theo has prior extensive experience in the digital health and pharmaceutical industries, having held positions at Science 37 and Amgen. He has also led digital health consulting engagement for various tech and healthcare brands. He holds an MBA from Duke University - Fuqua School of Business, an MPhil in Technology Policy from Cambridge University and a BsC in Molecular Medicine from the University of Sussex, UK.